Technical Analysis for APLS - Apellis Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade B 19.1 -1.90% -0.37
APLS closed down 1.9 percent on Friday, May 24, 2019, on 44 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Up
See historical APLS trend table...

Date Alert Name Type % Chg
Fell Below 50 DMA Bearish 0.00%
20 DMA Support Bullish 0.00%
20 DMA Support Bullish -1.90%
Crossed Above 50 DMA Bullish -1.90%
MACD Bullish Centerline Cross Bullish -1.90%
180 Bullish Setup Bullish Swing Setup -1.90%
Stochastic Reached Overbought Strength -1.90%
Overbought Stochastic Strength -1.90%
Fell Below 50 DMA Bearish -0.73%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.73%

Older signals for APLS ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company's lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The Company is developing APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by subcutaneous injection, which is an injection into the tissue under the skin. It is developing APL-2 for the treatment of geographic atrophy (GA) and intermediate age-related macular degeneration (AMD) by intravitreal injection, which is an injection into the eye. The Company is developing APL-1 for the treatment of chronic obstructive pulmonary disease (COPD) by inhaled administration.
Medicine Biopharmaceutical Clinical Medicine Organ Systems Macular Degeneration Chronic Obstructive Pulmonary Disease Autoimmune And Inflammatory Diseases Paroxysmal Nocturnal Hemoglobinuria Acquired Hemolytic Anemia Treatment Of Chronic Obstructive Pulmonary Disease Complement System Pnh
Is APLS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 24.84
52 Week Low 11.45
Average Volume 445,457
200-Day Moving Average 16.787
50-Day Moving Average 19.2526
20-Day Moving Average 19.053
10-Day Moving Average 18.876
Average True Range 1.0207
ADX 10.63
+DI 20.0677
-DI 17.712
Chandelier Exit (Long, 3 ATRs ) 17.3979
Chandelier Exit (Short, 3 ATRs ) 20.4221
Upper Bollinger Band 20.1649
Lower Bollinger Band 17.9411
Percent B (%b) 0.52
BandWidth 11.671653
MACD Line 0.0206
MACD Signal Line -0.0217
MACD Histogram 0.0423
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 20.69
Resistance 3 (R3) 20.76 20.30 20.43
Resistance 2 (R2) 20.30 19.90 20.27 20.34
Resistance 1 (R1) 19.70 19.64 19.47 19.63 20.25
Pivot Point 19.24 19.24 19.13 19.21 19.24
Support 1 (S1) 18.64 18.84 18.41 18.57 17.95
Support 2 (S2) 18.18 18.58 18.15 17.86
Support 3 (S3) 17.58 18.18 17.78
Support 4 (S4) 17.51